
Molecular Conceptor - Table of Contents

Last updated on **February 2009**

A - DRUG DISCOVERY

1. Principles of Rational Drug Design
2. Structure Activity Relationships
3. Success Stories in Drug Discovery

B - ANALOG DESIGN AND MOLECULAR MIMICRY

1. Bioisosterism

C - SYNTHESIS AND LIBRARY DESIGN

1. Synthesis of Drugs
2. Library Design

D - ADME PROPERTIES AND PREDICTIONS

1. ADME Properties

E - STRUCTURE-BASED DESIGN

1. Introduction to Protein-Ligand Binding

F - CHEMINFORMATICS

1. Molecular Similarity

G - LIGAND-BASED DESIGN

1. Principles in Pharmacophore Elucidation

H - QSAR AND CHEMOMETRICS

1. QSAR: Principles and Methods

I - MOLECULAR BASIS OF DRUGS

1. Molecular Geometry
2. Molecular Properties
3. Stereochemistry
4. Molecular Energies
5. Conformational Analysis
6. Molecular Graphics

7. Selected Examples in 3D Analysis

J - GENERAL TOPICS

1. General Introduction to Drugs
2. Drug Discovery
3. Drug Development



A. DRUG DISCOVERY

○ A1. PRINCIPLES OF RATIONAL DRUG DESIGN

- A1.1 Rational Drug Design
 - A1.1.1 Drug Design Basis: Molecular Recognition
 - A1.1.2 Lock-and-Key Model
 - A1.1.3 Induced-Fit Model
 - A1.1.4 Rational Drug Design
 - A1.1.5 Rational Drug Design Process
 - A1.1.6 Receptor-Based Drug Design
 - A1.1.7 Pharmacophore-Based Drug Design
- A1.2 Pharmacophore-Based Design
 - A1.2.1 Pharmacophore-Based Drug Design Approach
 - A1.2.2 Similarity Concepts and Molecular Mimicry
 - A1.2.3 Examples of Molecular Mimicry
 - A1.2.4 ATP
 - A1.2.5 Dopamine
 - A1.2.6 Histamine
 - A1.2.7 Estradiol
 - A1.2.8 Peptidomimetics
 - A1.2.9 Strengths of Pharmacophore-Based Drug Design
- A1.3 Receptor-Based Design
 - A1.3.1 Design by Direct Interaction with Receptor Sites
 - A1.3.2 Exploiting the Receptor Recognition Concepts
 - A1.3.3 Initial Data in Receptor-Based Drug Design
 - A1.3.4 Strengths of Receptor Based Drug Design
- A1.4 Integration in a Global Perspective
 - A1.4.1 Typical Projects
 - A1.4.2 Exploit the Two Methods, Independently
 - A1.4.3 Synergy Between the Two Approaches
 - A1.4.4 Example of Synergy Between the Two Approaches
 - A1.4.5 Good Binding Models, the Synergy Condition
 - A1.4.6 Ideal Situation
 - A1.4.7 Example 1
 - A1.4.8 Example 2
 - A1.4.9 Integration in a Global Perspective
 - A1.4.10 Pharmacophore-Based Drug Design
 - A1.4.11 Receptor-Based Drug Design
 - A1.4.12 Integrated Global Approach
- A1.5 Challenge of the Genomics Era
 - A1.5.1 The Genomic Era
 - A1.5.2 A New Challenge in Drug Design

- A1.6 Typical Projects
 - A1.6.1 Typical Pharmacophore-Based Project
 - A1.6.2 Design Based on 3D Mimicry
 - A1.6.3 Typical Receptor-Based Project
 - A1.6.4 Design Based in Making Favorable 3D Interactions
 - A1.6.5 Typical Genomic Project
 - A1.7 Perspectives
 - A1.7.1 Drug Discovery of the 1970's
 - A1.7.2 Drug Discovery of the 1980's
 - A1.7.3 Drug Discovery of the 1990's
 - A1.7.4 The Present Situation
 - A1.7.5 Initial Skepticism Towards Rational Drug Design
 - A1.7.6 Success Stories in Rational Drug Design
 - A1.7.7 Future Perspectives
 - A1.8 CHAPTER QUIZZES (Available only in Teaching Package)
-

○ A2. STRUCTURE ACTIVITY RELATIONSHIPS

- A2.1 Introduction
 - A2.1.1 Structure Activity Relationships (SAR)
 - A2.1.2 Aim of SAR Analyses
 - A2.1.3 Results of a SAR Analysis
 - A2.1.4 Principle: Alteration of an Active Substance
 - A2.1.5 Development: a Single Modification at a Time
 - A2.1.6 Iterative Process
 - A2.1.7 Chemical Modifications and Medicinal Chemist Tools
 - A2.1.8 Chemistry is the Limiting Factor
 - A2.1.9 Role of the Functional Groups in the Reference Structure
- A2.2 Probing H-Bond Interactions
 - A2.2.1 Principle for Probing Hydrogen Bond Interactions
 - A2.2.2 Hydroxyl: Hypothetical H-Bond Interactions
 - A2.2.3 Testing the Existence of H-Bond Interactions
 - A2.2.4 Testing H-Bond Donor Capability of the Hydroxyl
 - A2.2.5 Testing H-Bond Acceptor Capability of the Hydroxyl
 - A2.2.6 Example 1: Pyrazolopyrimidines
 - A2.2.7 Example 2: Benzimidazoles
 - A2.2.8 Example 3: Pyrrolopyrimidine
 - A2.2.9 Example 4: Salicylanilides
 - A2.2.10 Example 5: Isoflavones
 - A2.2.11 Carbonyl: Hypothetical H-Bond Interactions
 - A2.2.12 Testing the Existence of H-Bond Interactions
 - A2.2.13 Example 1: Aminobenzophenones
 - A2.2.14 Example 2: Thiazolidine-dione
 - A2.2.15 Example 3: Pyrazolopyridines
 - A2.2.16 Example 4: Naphthyl Ketones
 - A2.2.17 Example 5: Cyclic Peptides
 - A2.2.18 Amide
 - A2.2.19 Testing the Existence of H-Bond Interactions
 - A2.2.20 Testing H-Bond Acceptor Capability of the Carbonyl
 - A2.2.21 Testing H-Bond Donor Capability of the Nitrogen
 - A2.2.22 Example 1: Lactam Tricyclic
 - A2.2.23 Example 2: Pyrrolopyrimidinones
 - A2.2.24 Primary Amines
 - A2.2.25 Testing the Existence of H-Bond Interactions

- A2.2.26 Testing H-Bond Donor Capability of the Amines
- A2.2.27 Example 1: Imidazole Acetic Acids
- A2.2.28 Example 2: Salicylanilides
- A2.2.29 Secondary Amines
- A2.2.30 Testing the Existence of H-Bond Interactions
- A2.2.31 Testing H-Bond Donor Capability of the Amines
- A2.2.32 Example 1: Imidazoquinoxalines
- A2.2.33 Example 2: Anilinopyrimidines
- A2.2.34 Example 3: Aminoquinazolines
- A2.2.35 Browser of Aminoquinazolines Analogs
- A2.2.36 Tertiary Amines
- A2.2.37 Testing the Existence of H-Bond Interactions
- A2.2.38 Example Dihydropyridopyrimidones
- A2.2.39 Aromatic Nitrogens
- A2.2.40 Testing the Existence of H-Bond Interactions
- A2.2.41 Testing H-Bond Donor Capability of the Amines
- A2.2.42 Example 1: Imidazoles and Oxazoles
- A2.2.43 Example 2: Pyrrolyl Ureas
- A2.2.44 Example 3: Anilinoquinazolines
- A2.2.45 Example 3: X-Ray Data
- A2.2.46 Carboxylic Acids
- A2.2.47 Testing the Existence of H-Bond Interactions
- A2.2.48 Testing H-Bond Donor Capability of the COOH
- A2.2.49 Example 1: Imidazole Carboxylic Acids
- A2.2.50 Example 2: Pyrrolopyrimidines
- A2.2.51 Example 3: Peptide-Based Structures
- A2.2.52 Example 4: Aminoquinolones
- A2.2.53 Ethers
- A2.2.54 Testing the Existence of H-Bond Interactions
- A2.2.55 Example 1: Epothilone A
- A2.2.56 Example 2: Clofibrate
- A2.2.57 Example 3: Piperidine Renin Inhibitors
- A2.2.58 Cyano
- A2.2.59 Testing the Existence of H-Bond Interactions
- A2.2.60 Example 1: Anilinopyrimidines
- A2.2.61 Example 2: Quinolinecarbonitriles
- A2.2.62 Example 3: Pyrrolopyrimidines

- A2.3 Probing Ionic Interactions
 - A2.3.1 Principle for Probing Ionic Interactions
 - A2.3.2 Carboxylates
 - A2.3.3 Amines

- A2.4 Probing Hydrophobic Interactions
 - A2.4.1 Importance of Hydrophobic Interactions
 - A2.4.2 Principles for Probing Hydrophobic Interactions
 - A2.4.3 Alteration of Ring Size
 - A2.4.4 Example 1: Probing of a Hydrophobic Pocket
 - A2.4.5 Example 2 : Varying Ring Size
 - A2.4.6 Example 3: Probing a Hydrophobic Pocket
 - A2.4.7 Example 4: Fusion with Additional Rings
 - A2.4.8 Homologation of Alkyl Chains
 - A2.4.9 Example 1 of Homologation
 - A2.4.10 Example 2 of Homologation
 - A2.4.11 Example 3 of Homologation
 - A2.4.12 Exploring the Width of a Hydrophobic Pocket
 - A2.4.13 Example 1: Pyrazoles
 - A2.4.14 Example 2: Indolinones
 - A2.4.15 Variations with the Pyrrole Moiety
 - A2.4.16 X-Ray Data of Indolinone Analog

- A2.4.17 Example 3: Pyridopyrimidines
- A2.4.18 X-Ray Data with Pyridopyrimidine Structure
- A2.4.19 Probing the Polarity of a Pocket
- A2.4.20 Example: Dopamine Antagonists

- **A2.5 Probing Other Interactions**
 - A2.5.1 Halogens
 - A2.5.2 Example 1: COX-2
 - A2.5.3 Example 2: MDM2
 - A2.5.4 Example 3: Glycine Antagonists
 - A2.5.5 Example 4: EGF-R Kinase Inhibitors
 - A2.5.6 Probing Aromatic Ring Positions
 - A2.5.7 KDR Inhibitors
 - A2.5.8 Anthranilamide - Factor Xa Inhibitors
 - A2.5.9 Exploration of Anthranilamide Substitution
 - A2.5.10 Replacement of the Benzothiophene Ring
 - A2.5.11 Useful Data Collected for Understanding SAR
 - A2.5.12 Tetrahydroisoquinoline - Serotonin 5-HT_{2A} Ligands
 - A2.5.13 Preferred Position for the Chlorine
 - A2.5.14 Most Potent Analogs

- **A2.6 Modifications to Alter the Geometry of the Ligand**
 - A2.6.1 Modification to Alter the Geometry of the Ligand
 - A2.6.2 The Amide Function
 - A2.6.3 SAR Example with an Amide Moiety
 - A2.6.4 Ortho Substitution of Aromatic Ring
 - A2.6.5 Cis-Trans Isomers
 - A2.6.6 Example 1: Cis and Trans Isomers
 - A2.6.7 Z and E Isomers are in Equilibrium !
 - A2.6.8 Example 2: Cis and Trans Isomers
 - A2.6.9 Alter Stereochemistry
 - A2.6.10 Rigid Analogs: SAR Principle
 - A2.6.11 Example 1: GnRH Antagonists Rigidification
 - A2.6.12 Example 2: AChE Rigidification
 - A2.6.13 Example 3: p56-lck Inhibitors Rigidification
 - A2.6.14 Example 4: Angiotensin-II Receptor Antagonists
 - A2.6.15 Example 5: Dopaminergics Rigidification
 - A2.6.16 Examples 6: Pseudo Rings
 - A2.6.17 Anthranilamides
 - A2.6.18 Phenoxyphenyltriazoles
 - A2.6.19 Salicylanilides
 - A2.6.20 Example 7: Good and Bad Rigidification
 - A2.6.21 Example 8: Rigidification of a Flexible Molecule
 - A2.6.22 Flexible Analogs: SAR Principle
 - A2.6.23 Ring Suppression: Doxepin
 - A2.6.24 Alteration of Interatomic Distances
 - A2.6.25 Alteration of the Stereochemistry of the Ligand

- **A2.7 Complexity of SAR Analyses**
 - A2.7.1 Complexity of the Structures Concerned
 - A2.7.2 Observations with no Explanations
 - A2.7.3 Local Changes and Global Consequences
 - A2.7.4 Small Modification that Substantially Alters the Geometry
 - A2.7.5 Small Modification that Interferes with Other Interactions
 - A2.7.6 Modification that Alters the Binding Orientation
 - A2.7.7 Change that Alters a Characteristic of the Substance
 - A2.7.8 pKa
 - A2.7.9 LogP
 - A2.7.10 Non Additivity of Biological Effects
 - A2.7.11 Additivity in Steroids: Norethisterone

- A2.7.12 Additivity of Biological Effects
- A2.7.13 Non Additivity of Biological Effects
- A2.7.14 Furanyl Example: Non-Additivity
- A2.7.15 Phenoxypyrimidines: Non Additivity
- A2.7.16 Being Trapped with Poor Biological Activities
- A2.7.17 The Dioxobenzothiazole Scaffold
- A2.7.18 Origin of the Problem
- A2.7.19 The Combinatorial Era
- **A2.8 Example of Good Exploitation of SAR Complexity**
 - A2.8.1 The Banyu Story with the Urea Structure
 - A2.8.2 Importance of the Entire Urea Moiety
 - A2.8.3 Bioactive Conformation?
 - A2.8.4 Design of Compounds with a Cis Conformation
 - A2.8.5 Good Exploitation of the SAR Analyses
- **A2.9 CHAPTER QUIZZES (Available only in Teaching Package)**



○ **A3. SUCCESS STORIES IN DRUG DISCOVERY**

- **A3.1 Success Story-1 : Captopril**
 - A3.1.1 Captopril
 - A3.1.2 Captopril Target - ACE
 - A3.1.3 Starting Point: Venom Causes Drop in Blood Pressure
 - A3.1.4 Snake Venom Acts on the ACE Cascade
 - A3.1.5 The Captopril Story
 - A3.1.6 Developing an Assay for ACE
 - A3.1.7 Isolating and Purifying the Venom Peptides
 - A3.1.8 Encouraging Clinical Trial Results
 - A3.1.9 Project Virtually Abandoned at Squibb
 - A3.1.10 Back to the Project
 - A3.1.11 Applying the Concepts to ACE
 - A3.1.12 The Basis of ACE and CPA Similarity
 - A3.1.13 X-ray Structure of CPA
 - A3.1.14 Modeling the Active Site of ACE (1/4)
 - A3.1.15 Modeling the Active Site of ACE (2/4)
 - A3.1.16 Modeling the Active Site of ACE (3/4)
 - A3.1.17 Modeling the Active Site of ACE (4/4)
 - A3.1.18 Design of a Novel ACE Inhibitor
 - A3.1.19 The Phe-Ala-Pro Pharmacophore
 - A3.1.20 Finding a Lead Compound
 - A3.1.21 The Discovery of Captopril
 - A3.1.22 The Captopril Project Timeline
 - A3.1.23 What Made the Success of the Project Possible?
 - A3.1.24 Structure-Based Component
 - A3.1.25 Ligand-Based Component
 - A3.1.26 Following the Discovery
 - A3.1.27 Recent Structure of Captopril-ACE Complex
 - A3.1.28 Other Drugs in This Class
- **A3.2 Success Story-2 : Aliskiren**
 - A3.2.1 Aliskiren
 - A3.2.2 Aliskiren Target - Renin
 - A3.2.3 Starting Point
 - A3.2.4 The Aliskiren Story
 - A3.2.5 The First Generation of Renin Inhibitors
 - A3.2.6 The Second Generation of Renin Inhibitors

- A3.2.7 Peptidomimetic Approach was Unsuccessful
- A3.2.8 The Need for a New Non-Peptidic Scaffold
- A3.2.9 Novartis's New Rational Approach
- A3.2.10 3D Model of the Enzyme
- A3.2.11 Predicting the Bioactive Conformation of CGP38560
- A3.2.12 The Design Strategy
- A3.2.13 Finding a Feasible Scaffold
- A3.2.14 Criteria for Good Candidate Molecules
- A3.2.15 The Parallel Design of Non-Peptide Renin Inhibitors
- A3.2.16 The THQ Series
- A3.2.17 Validation of the Design Strategy
- A3.2.18 The Phenoxy Series
- A3.2.19 Optimization of the Phenoxy Lead
- A3.2.20 The Indole Series
- A3.2.21 The Salicylamide Series
- A3.2.22 A Docking Experiment
- A3.2.23 Design of the Salicylamide Molecule
- A3.2.24 Transferrable SAR's
- A3.2.25 Example of Transferrable SAR's
- A3.2.26 Four Unrelated Lead Compounds
- A3.2.27 Browser of the Novartis Renin Inhibitor Leads
- A3.2.28 From Initial Lead to Aliskiren
- A3.2.29 The Aliskiren Project Timeline
- A3.2.30 What Made the Success of the Project Possible?
- A3.2.31 The Incorporation of Modeling
- A3.2.32 Modeling - The Key to Aliskiren's Success
- A3.2.33 Historical Document
- A3.2.34 Good Teamwork
- A3.2.35 Following the Discovery
- A3.2.36 X-rays of Complex with CGP38560
- A3.2.37 X-ray Determination of Lead Inhibitors
- A3.2.38 The Indole X-ray
- A3.2.39 The S3sp sub-Pocket
- A3.2.40 Other Work on Drugs in this Class



B. ANALOG DESIGN AND MOLECULAR MIMICRY

○ B1. BIOISOSTERISM

■ B1.1 Introduction

- B1.1.1 What is Bioisosterism?
- B1.1.2 History of the Concept of Bioisosterism
- B1.1.3 Langmuir (1919): Comolecules and Isosteres
- B1.1.4 Grimm (1925)
- B1.1.5 Erlenmeyer (1932)
- B1.1.6 Friedman (1951): Concept of Bioisosteres
- B1.1.7 Thornber (1979)
- B1.1.8 Burger (1991)
- B1.1.9 Cheminformatics Era (1993)
- B1.1.10 Remark on Stereochemical Aspects

■ B1.2 Typical Isosteres

- B1.2.1 Classification of Typical Isosteres
- B1.2.2 Monovalent Atoms or Groups
- B1.2.3 Divalent Isosteres
- B1.2.4 Trivalent Atoms or Groups


- B1.2.5 Tetrasubstituted Atoms
 - B1.2.6 Ring Equivalents
- B1.3 Medicinal Chemistry Use
 - B1.3.1 A Simple Concept for Many Applications
 - B1.3.2 Adapt Chemical Structures to Feasible Syntheses
 - B1.3.3 Change the Type of Biological Activity
 - B1.3.4 Example 1: Tricyclic Structures
 - B1.3.5 Example 2: Angiotensin-II Receptor Ligands
 - B1.3.6 Example 3: Steroid Analogs
 - B1.3.7 Achieve Patentability
 - B1.3.8 Mimic an Endogenous Ligand
 - B1.3.9 Improve Potency
 - B1.3.10 Improve Selectivity
 - B1.3.11 Reduce Side Effects
 - B1.3.12 Reduce Toxicity
 - B1.3.13 Improve Bioavailability
 - B1.3.14 Exploit Metabolism
 - B1.3.15 Modify pKa
 - B1.3.16 Increase Chemical Stability
 - B1.3.17 Combinatorial Chemistry
- B1.4 Examples of Natural Bioisosteres
 - B1.4.1 Bioisosteres in Nature
 - B1.4.2 Aminoacids
 - B1.4.3 Nucleotides
 - B1.4.4 Sugars
 - B1.4.5 Lipids
 - B1.4.6 Steroid Hormones
 - B1.4.7 Carbohydrates
 - B1.4.8 Catecholamines
 - B1.4.9 Penicillins and Cephalosporins
- B1.5 Dictionary of Bioisosteres
 - B1.5.1 Dictionary of Bioisosteric Replacements
 - B1.5.2 Allyl
 - B1.5.3 Amide
 - B1.5.4 Amino-Acids
 - B1.5.5 Azomethine
 - B1.5.6 Benzene
 - B1.5.7 Carbonyl
 - B1.5.8 Carboxylic Acid
 - B1.5.9 Catechol
 - B1.5.10 Ester
 - B1.5.11 Halogen
 - B1.5.12 Hydrogen
 - B1.5.13 Hydroxyl
 - B1.5.14 Indole
 - B1.5.15 Isopropyl
 - B1.5.16 Naphthalene
 - B1.5.17 Peptide Surrogates
 - B1.5.18 Phenol
 - B1.5.19 Pyridine
 - B1.5.20 Ring
 - B1.5.21 Sulfonyl
 - B1.5.22 Spacer
 - B1.5.23 Thioether
 - B1.5.24 Thiourea
- B1.6 Examples of Bioisosteric Transformations

- B1.6.1 Four Types of Bioisosteric Transformations
- B1.6.2 Ring-to-Ring Transformations
- B1.6.3 Example 1
- B1.6.4 Example 2
- B1.6.5 Example 3
- B1.6.6 Chain-to-Ring Transformations
- B1.6.7 Example 1
- B1.6.8 Example 2
- B1.6.9 Example 3
- B1.6.10 Ring-to-Chain Transformations
- B1.6.11 Example 1
- B1.6.12 Example 2
- B1.6.13 Example 3
- B1.6.14 Chain-to-Chain Transformations
- B1.6.15 Example 1
- B1.6.16 Example 2
- B1.6.17 Example 3

- **B1.7 Commercial Bioisosteric Drugs: Examples**
 - B1.7.1 Angiotensin Receptor Blockers (ARBs)
 - B1.7.2 COX-2 Inhibitors
 - B1.7.3 Anti-Inflammatory NSAIDs
 - B1.7.4 Antiarrhythmic Beta-Adrenergics
 - B1.7.5 Neuroleptics
 - B1.7.6 Anti-Ulcers
 - B1.7.7 Male Erectile Dysfunction Drugs
 - B1.7.8 Benzodiazepines
 - B1.7.9 Antibacterial Sulfonamides
 - B1.7.10 Beta-Lactam Antibiotics
 - B1.7.11 Local Anesthetics
 - B1.7.12 Glucocorticoid Steroids
 - B1.7.13 Statin Drugs

- **B1.8 Patent Issues with Bioisosterism**
 - B1.8.1 Limits of Patent Infringements on Structures?
 - B1.8.2 The Viagra-Levitra Case
 - B1.8.3 The Diazepam-Clobazam Example
 - B1.8.4 Patent Issues with Chiral Enantiomers
 - B1.8.5 Patentable Drugs by Bioisosterism

- **B1.9 Programs and Databases on Bioisosterism**
 - B1.9.1 Computerized Systems
 - B1.9.2 EMIL Program
 - B1.9.3 BIOISOSTER Program and BIOSTER Database
 - B1.9.4 The BIOISOSTER Program
 - B1.9.5 Bioisosteric Morphing of the Query
 - B1.9.6 The Accelrys BIOSTER Database
 - B1.9.7 Example of BIOSTER Database Content
 - B1.9.8 BROOD Program
 - B1.9.9 Brood Program for Bradykinin Antagonists
 - B1.9.10 Organon IBIS Program
 - B1.9.11 Novartis Program for Ring Bioisosteres
 - B1.9.12 GlaxoSmithKline Program for Ring Replacements
 - B1.9.13 COSMOsim Program for Bioisosteric Similarity
 - B1.9.14 Cheminformatics Software
 - B1.9.15 Daylight: MERLIN Program
 - B1.9.16 Tripos: SYBYL Platform
 - B1.9.17 MDL: ISENTRIS Program
 - B1.9.18 MDL: DiscoveryGate Program
 - B1.9.19 CAS: SciFinder Program

- **B1.10 Review Articles and Books**
 - B1.10.1 Review Articles on Bioisosterism
 - B1.10.2 Books on Bioisosterism
 - **B1.11 Limitations and the Future**
 - B1.11.1 The Receptor is the Ultimate Decider
 - B1.11.2 The Multidimensional Nature of Bioisosterism
 - B1.11.3 Shape
 - B1.11.4 Lipophilicity
 - B1.11.5 Electronic Distribution
 - B1.11.6 Hydrogen-Bond Capacity
 - B1.11.7 Can Bioisosterism be Quantified?
 - B1.11.8 The Cheminformatics Era
 - B1.11.9 Docking can be used to Generate Bioisosteres
 - B1.11.10 Strategic and Financial Considerations
 - B1.11.11 Examples of Success and Failures
 - **B1.12 CHAPTER QUIZZES (Available only in Teaching Package)**
- 

C. SYNTHESIS AND LIBRARY DESIGN

○ C1. SYNTHESIS OF DRUGS

- **C1.1 Introduction**
 - C1.1.1 Why to Synthesize a New Molecule?
 - C1.1.2 Drug Discovery
 - C1.1.3 Bulk Production
 - C1.1.4 Goal of the Synthesis
 - C1.1.5 General Requirements before Starting
 - C1.1.6 Number of Steps and Intermediates
 - C1.1.7 Measurable Reaction's Characteristics
 - C1.1.8 Yield
 - C1.1.9 Reaction Rate
 - C1.1.10 Product Selectivity
 - C1.1.11 Regioselectivity and Regiospecificity
 - C1.1.12 Stereoselectivity and Stereospecificity
 - C1.1.13 Thermodynamic and Kinetic Properties of the Reaction
 - C1.1.14 Thermodynamics
 - C1.1.15 Kinetics
 - C1.1.16 Determinants of a Chemical Reaction
 - C1.1.17 Steric Effects
 - C1.1.18 Electronics Effects
 - C1.1.19 Solvent Effects
 - C1.1.20 How to Influence a Reaction?
 - C1.1.21 Reactant Choice
 - C1.1.22 Reagent Choice
 - C1.1.23 Reaction Conditions
 - C1.1.24 Influence of pH
 - C1.1.25 Influence of the Solvent
 - C1.1.26 Catalysts
 - C1.1.27 Tools for Following the Progression of a Reaction
 - C1.1.28 Spectroscopy
 - C1.1.29 Mass Spectra (MS)
 - C1.1.30 Infrared (IR)
 - C1.1.31 Nuclear Magnetic Resonance (NMR)
 - C1.1.32 Ultraviolet (UV)

- C1.1.33 Circular Dichroism (CD) and Optical Rotatory Dispersion (ORD)
- C1.1.34 X-rays
- C1.1.35 Chromatography
- C1.1.36 High Performance Liquid Chromatography (HPLC)
- C1.1.37 Chiral Chromatography

- C1.2 Design Strategy
 - C1.2.1 Strategy Like a General in the Battle
 - C1.2.2 Flexibility in the Strategy
 - C1.2.3 Flexibility in the Synthetic Program
 - C1.2.4 Flexibility in the Target Molecule
 - C1.2.5 Nicolaou Statement on the Trip to Ithaca
 - C1.2.6 Linear and Convergent Strategy
 - C1.2.7 Linear Strategy
 - C1.2.8 Example: Captopril Linear Synthesis
 - C1.2.9 Convergent Strategy
 - C1.2.10 Convergent Advantage
 - C1.2.11 Example: Losartan Convergent Synthesis
 - C1.2.12 How to Analyze a Molecule for Synthesis?
 - C1.2.13 Three Methods for the Design of a Synthetic Program
 - C1.2.14 Adapt Known Synthetic Schemes
 - C1.2.15 Literature and Patent Searches
 - C1.2.16 Database Searching with Computer Programs
 - C1.2.17 Consider a Building Block Strategy
 - C1.2.18 Small Commercial Building Blocks
 - C1.2.19 Elaborated Building Blocks
 - C1.2.20 Starting from Scratch - Retrosynthetic Analysis
 - C1.2.21 Retrosynthetic Strategy
 - C1.2.22 Disconnection of Strategic Bonds
 - C1.2.23 Strategic Bonds Revealed by Small Modifications
 - C1.2.24 FGA
 - C1.2.25 FGI
 - C1.2.26 FGR
 - C1.2.27 The Retrosynthetic Process
 - C1.2.28 From TC to SM
 - C1.2.29 The Synthetic Program
 - C1.2.30 The Tetrodotoxin Example
 - C1.2.31 Simple Exercise in Retrosynthesis
 - C1.2.32 Retrosynthesis
 - C1.2.33 Synthesis
 - C1.2.34 Disconnection Methods for Retrosynthesis
 - C1.2.35 Homolytic Disconnection
 - C1.2.36 Heterolytic Disconnection
 - C1.2.37 Pericyclic Bond Disconnection
 - C1.2.38 Combining the Three Synthetic Methods

- C1.3 Synthetic Tactic
 - C1.3.1 Principles of Synthetic Tactics
 - C1.3.2 Reaction Classifications
 - C1.3.3 By Changes Occurring in the Reactant Molecules
 - C1.3.4 By Reaction Types
 - C1.3.5 By Functional Groups
 - C1.3.6 Protecting Groups
 - C1.3.7 Protecting Reactive Centers
 - C1.3.8 Requirements for Protecting Groups
 - C1.3.9 Protection and Deprotection of Amino Acids
 - C1.3.10 Examples of Protecting Groups
 - C1.3.11 Alcohol Protection
 - C1.3.12 Carboxylic Acid Protection
 - C1.3.13 Amine Protection

- C1.3.14 Phenol Protection
- C1.3.15 How to Assess the Quality of a Synthesis?
- C1.3.16 Syntheses of Swainsonine
- **C1.4 Stereochemical Issues**
 - C1.4.1 Why Chiral Drugs?
 - C1.4.2 Examples of Chiral Drugs
 - C1.4.3 Multiple Aspects of Molecular Chirality
 - C1.4.4 Active and Inactive Enantiomers
 - C1.4.5 'Chiral Switch' : From a Racemic to a Chiral Drug
 - C1.4.6 Advantages of Single Enantiomer Drugs
 - C1.4.7 Pharmacokinetic Properties
 - C1.4.8 Perhexiline
 - C1.4.9 Selectivity
 - C1.4.10 Ritalin
 - C1.4.11 Penicillamine
 - C1.4.12 Ethambutol
 - C1.4.13 Ketamine
 - C1.4.14 L-Dopa
 - C1.4.15 Patent Position
 - C1.4.16 Three Methods to Obtain Chiral Molecules
 - C1.4.17 Racemic Route
 - C1.4.18 Resolution of Racemates
 - C1.4.19 Example of Industrial Racemate Separation
 - C1.4.20 Advantages of the Process Chosen
 - C1.4.21 Recycling Undesired Enantiomer
 - C1.4.22 Sometimes Separation very Difficult
 - C1.4.23 When Too Many Chiral Centers
 - C1.4.24 Asymmetric Route
 - C1.4.25 Chiral Reagents and Reactants
 - C1.4.26 Chiral Catalysts
 - C1.4.27 Asymmetric Synthesis in R&D.
 - C1.4.28 Extraction From Natural Sources
 - C1.4.29 Stereoselectivity of Action not Always Predictable
 - C1.4.30 Spontaneous Enantiomer Interconversion
- **C1.5 Structural Diversity and Higher Level Synthetic Strategies**
 - C1.5.1 Diverse Strategy in Drug Discovery
 - C1.5.2 Introducing Diversity in the Reagents
 - C1.5.3 Introducing Diversity at the Proper Time
 - C1.5.4 Late Stage Introduction of Diversity
 - C1.5.5 Early Stage Introduction of Diversity
 - C1.5.6 Diversity Space Restricted by Synthetic Route
 - C1.5.7 Consider Alternative Syntheses
 - C1.5.8 Example of Introduction of Diversity
 - C1.5.9 Combinatorial Chemistry
 - C1.5.10 Diversity-Oriented Synthesis (DOS)
 - C1.5.11 Maximizing the Chance to Find a Hit
 - C1.5.12 Example of Diversity-Oriented Synthesis
 - C1.5.13 Higher Level Strategies in Organic Synthesis
- **C1.6 Synthesis of Some Common Drugs**
 - C1.6.1 Introduction to Synthetic Schemes
 - C1.6.2 Benzocaine
 - C1.6.3 Retrosynthetic Scheme
 - C1.6.4 Benzocaine Synthesis
 - C1.6.5 Physico-Chemical Properties of Benzocaine
 - C1.6.6 Aspirin
 - C1.6.7 Aspirin Synthesis
 - C1.6.8 Physico-Chemical Properties of Aspirin

- C1.6.9 Nalidixic Acid
- C1.6.10 Retrosynthetic Scheme
- C1.6.11 Nalidixic Acid Synthesis
- C1.6.12 Physico-Chemical Properties of Nalidixic Acid
- C1.6.13 Zidovudine (AZT)
- C1.6.14 Retrosynthetic Scheme
- C1.6.15 AZT Synthesis
- C1.6.16 Another Synthesis for AZT
- C1.6.17 Which Route is Preferable?
- C1.6.18 Physico-Chemical Properties of Zidovudine
- C1.6.19 Terfenadine
- C1.6.20 Retrosynthetic Scheme
- C1.6.21 Terfenadine Synthesis
- C1.6.22 Physico-Chemical Properties of Terfenadine
- C1.6.23 Nifedipine
- C1.6.24 Simple Retrosynthesis of Nifedipine
- C1.6.25 One-Pot Synthesis of Nifedipine
- C1.6.26 Two Steps Retrosynthesis Scheme of Nifedipine
- C1.6.27 Two Steps Synthesis of Nifedipine
- C1.6.28 Physico-Chemical Properties of Nifedipine
- C1.6.29 Sildenafil (Viagra)
- C1.6.30 Retrosynthetic Scheme
- C1.6.31 Sildenafil Synthesis
- C1.6.32 Physico-Chemical Properties of Sildenafil

- C1.7 Programs for Computer-Aided Synthesis
 - C1.7.1 Programs for Computer-Aided Synthesis
 - C1.7.2 Retrosynthetic Programs
 - C1.7.3 LHASA
 - C1.7.4 SYNCHEM
 - C1.7.5 SECS, OCCS, CASP
 - C1.7.6 Formal and Mathematically-Based Programs
 - C1.7.7 IGOR
 - C1.7.8 EROS
 - C1.7.9 SYNGEN
 - C1.7.10 RAIN
 - C1.7.11 Forward Reaction Predictions
 - C1.7.12 CAMEO
 - C1.7.13 CHIRON
 - C1.7.14 WODCA
 - C1.7.15 Other Programs
 - C1.7.16 AIPHOS
 - C1.7.17 CAESA
 - C1.7.18 AOCC
 - C1.7.19 SYSTEMATICHEM

- C1.8 Databases for Organic Synthesis
 - C1.8.1 Databases for Organic Synthesis
 - C1.8.2 Printed Information
 - C1.8.3 Specialized Abstracting Services
 - C1.8.4 Chemical Abstracts Services (CAS)
 - C1.8.5 SciFinder
 - C1.8.6 Beilstein
 - C1.8.7 Gmelin
 - C1.8.8 Reaction Databases
 - C1.8.9 On-Line Resources
 - C1.8.10 Patent Databases
 - C1.8.11 US Patents: USPTO
 - C1.8.12 European Patents: EPOLINE
 - C1.8.13 Other Patent Databases



○ C2. LIBRARY DESIGN

■ C2.1 Introduction

- C2.1.1 Libraries of Molecules Prepared One by One
- C2.1.2 The Combinatorial Chemistry Boom
- C2.1.3 Initial Disappointments
- C2.1.4 The Quest of Quality
- C2.1.5 Chemical Diversity Space
- C2.1.6 Library Representation
- C2.1.7 Definition of a Virtual Library
- C2.1.8 Scaffolds-Substituents-Reactions

■ C2.2 The Basis of a Good Scaffold

- C2.2.1 Scaffold: the First Piece of a Complex Jigsaw Puzzle
- C2.2.2 Cyclic and Acyclic Scaffold
- C2.2.3 The Scaffold, a Fuzzy Concept
- C2.2.4 The Scaffold Names
- C2.2.5 Scaffold Requirements
- C2.2.6 Scaffold and ADME Properties
- C2.2.7 Geometrical Requirements
- C2.2.8 Avoid Clashes with the Receptor
- C2.2.9 Good Binding Interactions With the Scaffold
- C2.2.10 Good Vector Orientation
- C2.2.11 Patent Position and Novelty
- C2.2.12 Problems of Scaffolds Patentability
- C2.2.13 Patentable Scaffold
- C2.2.14 Validation of Novelty
- C2.2.15 Syntheses Amenable to Combinatorial Chemistry
- C2.2.16 Bond-Formation for Array Synthesis Methods
- C2.2.17 Ideal Scaffold: a Multi-Project Template
- C2.2.18 A Universal Spacer as a Master Key
- C2.2.19 Diversity of the Space Covered by the Substituents
- C2.2.20 Benzodiazepine Scaffold as a Spacer
- C2.2.21 A Master Key Adapted for a Family
- C2.2.22 Sequence Similarity: Kinase Example
- C2.2.23 Sequence Similarity in CDKi Sub-Class
- C2.2.24 Gleevec: from PKC to Abl Inhibition
- C2.2.25 Modulation with Simplified Staurosporine Scaffolds
- C2.2.26 Quinazoline Scaffold

■ C2.3 Scaffold Selection and Design

- C2.3.1 Methods for Designing a new Scaffold
- C2.3.2 Small Modification of Known Scaffold
- C2.3.3 2D Similarity Searching
- C2.3.4 3D Superimpositions
- C2.3.5 Docking and Virtual Screening
- C2.3.6 3D Shape Searching
- C2.3.7 2D Pharmacophore Searching
- C2.3.8 3D Pharmacophore Searching
- C2.3.9 Vector Matching
- C2.3.10 Hybrids of Known Scaffolds
- C2.3.11 Creative Design

■ C2.4 Focused and Diverse Strategies

- C2.4.1 Library Design Goals

- C2.4.2 Library Design Assumptions - Similar Property Principle
- C2.4.3 Analogy with Battleships Game
- C2.4.4 Diversity Strategy
- C2.4.5 Molecular Diversity
- C2.4.6 Focused Strategies
- C2.4.7 Diverse vs. Focused
- C2.4.8 Library Design in the Global Drug Discovery Perspective
- C2.4.9 Informative Libraries
- C2.4.10 Commercial Informative Libraries

- **C2.5 Measuring Distances Between Molecules**
 - C2.5.1 Methods to Calculate Molecular Similarity
 - C2.5.2 The Distance-Based and the Binary-Based Methods
 - C2.5.3 The Property-Based Approach
 - C2.5.4 Molecules in the Space of their Relevant Properties
 - C2.5.5 From Molecular Properties to Molecular Descriptors
 - C2.5.6 High-Dimensionality Space of the Molecular Descriptors
 - C2.5.7 Similarity Coefficient and Distance Coefficient
 - C2.5.8 Euclidian Distance
 - C2.5.9 Tanimoto Coefficient
 - C2.5.10 The Structural Approach
 - C2.5.11 Relevant Structural Keys
 - C2.5.12 Extended 3D Fingerprints
 - C2.5.13 Example of Structural Key
 - C2.5.14 Similarity Coefficients and Distance Coefficients
 - C2.5.15 Binary Tanimoto Example
 - C2.5.16 Computational Speed
 - C2.5.17 Similarity Index of an Entire Library
 - C2.5.18 Huge Dataset of Undigested Information
 - C2.5.19 Principal Components Analysis

- **C2.6 Subset Selection Issues**
 - C2.6.1 Subset Selection Problem
 - C2.6.2 Illustration of the Subset Selection Problem
 - C2.6.3 The Systematic Route
 - C2.6.4 Systematic Assessment Impracticable
 - C2.6.5 Solving the Subset Selection Problem
 - C2.6.6 Distance-Based Methods
 - C2.6.7 Clustering Methods
 - C2.6.8 Cell-Based Partitioning
 - C2.6.9 Optimization of Diversity Function
 - C2.6.10 Principle of the Optimization
 - C2.6.11 Example of Selection of Diverse Compounds
 - C2.6.12 The Input
 - C2.6.13 Normalization of the Data
 - C2.6.14 The Results

- **C2.7 Reagent Selection**
 - C2.7.1 Cherry Picking Limitations
 - C2.7.2 Optimization of Diversity and Synthetic Issues
 - C2.7.3 Example of Optimization Algorithm
 - C2.7.4 Selecting Reagents is a Complex Issue

- **C2.8 Increasing the Quality of a Library (ADMET)**
 - C2.8.1 Failures in Clinical Trials
 - C2.8.2 Failure in Drug Discovery
 - C2.8.3 Early Integration of ADME Properties in Drug Discovery
 - C2.8.4 The Drug-Like Approach and the Predictive Approach
 - C2.8.5 The Drug-Like Approach: Identify Poor Candidates
 - C2.8.6 Structural Mimicry and ADME Properties Mimicry

- C2.8.7 The Rule-Based Approach
- C2.8.8 Lipinski Rules (Rule of 5)
- C2.8.9 MW Distribution
- C2.8.10 LogP Distribution
- C2.8.11 H-Bond Donor Distribution
- C2.8.12 H-Bond Acceptor Distribution
- C2.8.13 Total Analysis
- C2.8.14 Other Rules
- C2.8.15 Remove Too Flexible Molecules
- C2.8.16 Remove Molecules with too Many Rings
- C2.8.17 Remove Compounds with Known Toxic Moieties
- C2.8.18 Remove Compounds with Reactive Groups
- C2.8.19 Remove False-Positive Hits
- C2.8.20 Remove Poorly Soluble Compounds
- C2.8.21 Filter on Heteroatoms and Non-Organic Molecules
- C2.8.22 Remove Molecules with Multiple Chiral Centers
- C2.8.23 Tailor-Made Filtering
- C2.8.24 Assisting Medicinal Chemist Expertise and Intuition
- C2.8.25 Privileged Drug-Like Scaffolds
- C2.8.26 Building Blocks Based on Known Drugs
- C2.8.27 The Computational Approach
- C2.8.28 Prediction of Absorption
- C2.8.29 Prediction of Metabolism
- C2.8.30 Prediction of Distribution and Elimination
- C2.8.31 Prediction of Toxicity
- C2.8.32 Lack of Standardized ADMET Databases
- C2.8.33 Available Software

- C2.9 Example of Library Analysis
 - C2.9.1 Common Treatments in Library Analysis
 - C2.9.2 Import of Libraries in a Common Database
 - C2.9.3 Cleaning Up the Database
 - C2.9.4 Set Stereoisomers
 - C2.9.5 Assessing the Uniqueness of a Library
 - C2.9.6 Drug-Likeness: Lipinski Rule of 5
 - C2.9.7 Drug-Likeness: Other Filters
 - C2.9.8 Diversity Analysis with Molecular Descriptors
 - C2.9.9 Diversity Analysis with Fingerprints and PCA
 - C2.9.10 Final Results

- C2.10 CHAPTER QUIZZES (Available only in Teaching Package)



D. ADME PROPERTIES AND PREDICTIONS

○ D1. ADME PROPERTIES

- D1.1 Introduction
 - D1.1.1 Therapeutics
 - D1.1.2 Pharmacokinetics
 - D1.1.3 Pharmacodynamics
 - D1.1.4 Dose-Response Relationships
 - D1.1.5 The Drug Route
 - D1.1.6 Absorption
 - D1.1.7 Distribution
 - D1.1.8 Metabolism
 - D1.1.9 Excretion

- D1.1.10 Bioavailability
- D1.1.11 Dose-Response Relationship
- D1.1.12 Translocation of Drugs
- D1.1.13 Cell Membrane Architecture
- D1.1.14 Passive Diffusion
- D1.1.15 Lipid Solubility and Molecular Weight
- D1.1.16 Problems with Ionized Species
- D1.1.17 Endocytosis and Exocytosis
- D1.1.18 Carrier-Mediated Transport
- D1.1.19 Facilitated Diffusion
- D1.1.20 Active Transport
- **D1.2 Absorption**
 - D1.2.1 Drug Absorption
 - D1.2.2 Incomplete Absorption of Drug Dose
 - D1.2.3 Routes of Administration
 - D1.2.4 Properties of Drugs that Influence Absorption
 - D1.2.5 Lipophilicity and Membrane Penetration
 - D1.2.6 The Partition Coefficient
 - D1.2.7 pKa of a Drug and pH
 - D1.2.8 Water Solubility and Dissolution
- **D1.3 Distribution**
 - D1.3.1 Drug Distribution
 - D1.3.2 Drug Translocation and Distribution
 - D1.3.3 Site of Action
 - D1.3.4 Distribution is to Many Body Sites
 - D1.3.5 Apparent Volume of Distribution
 - D1.3.6 Vd and Drug Distribution Patterns
 - D1.3.7 Meaning of Vd
 - D1.3.8 Factors that Influence Drug Distribution
 - D1.3.9 Perfusion and Membrane Permeability
 - D1.3.10 Binding to Plasma Proteins
 - D1.3.11 Accumulation in Organs and Tissues
 - D1.3.12 Ion Trapping
 - D1.3.13 Biological Barriers (BBB, Placental, Blood-Testis)
 - D1.3.14 BBB can be Crossed with Active Transport Systems
 - D1.3.15 Chimeric Peptide Technology in Brain Drug Delivery
 - D1.3.16 Distribution as Equilibrium State
- **D1.4 Metabolism**
 - D1.4.1 Metabolism of Foreign Substances (Xenobiotics)
 - D1.4.2 Metabolic Reactions
 - D1.4.3 Pathways of Metabolism
 - D1.4.4 Chemistry of Phase I Metabolism
 - D1.4.5 Chemistry of Phase II Metabolism
 - D1.4.6 Metabolic Activation and Toxicification
 - D1.4.7 Sites of Drug Metabolism
 - D1.4.8 Drug Metabolizing Enzymes
 - D1.4.9 Cytochrome P-450 (CYP)
 - D1.4.10 Oxidative Metabolism by Cytochrome P-450 Enzymes
 - D1.4.11 Mechanism of Cytochrome P-450 Oxidation
 - D1.4.12 Metabolic Variability
 - D1.4.13 Genetic Polymorphisms
 - D1.4.14 Age
 - D1.4.15 A Drug Metabolism Inhibited by Another Drug
 - D1.4.16 Metabolism Increased by Enzymatic Induction
 - D1.4.17 Metabolism and Drug Design
 - D1.4.18 Hard Drugs
 - D1.4.19 Removing

- D1.4.20 Hiding
- D1.4.21 Stabilizing
- D1.4.22 Soft Drugs
- D1.4.23 Topical Use
- D1.4.24 Ultrashort Use
- D1.4.25 Oral Use
- D1.4.26 Pro-Drugs
- D1.4.27 Oral Absorption
- D1.4.28 Prolonged Activity
- D1.4.29 Improved Formulation
- D1.4.30 BBB Penetration
- D1.4.31 Tumor Targeting
- **D1.5 Excretion**
 - D1.5.1 Excretion
 - D1.5.2 Renal Excretion
 - D1.5.3 Glomerular Filtration
 - D1.5.4 Tubular Secretion
 - D1.5.5 Tubular Reabsorption
 - D1.5.6 Biliary Excretion
 - D1.5.7 Other Excretion Routes
 - D1.5.8 Clearance
 - D1.5.9 Half-life
- **D1.6 ADME in Drug Design**
 - D1.6.1 Failures in Drug Development
 - D1.6.2 Challenge of R&D Planning
 - D1.6.3 High-Throughput ADME Evaluations
 - D1.6.4 In Silico Prediction of ADME Properties
 - D1.6.5 Lipinski Rules and Drug-Like Properties
 - D1.6.6 More Insights into ADME Predictions



E. STRUCTURE-BASED DESIGN

○ E1. INTRODUCTION TO PROTEIN-LIGAND BINDING

- **E1.1 Introduction**
 - E1.1.1 Receptor-Based Drug Design
 - E1.1.2 Macromolecular Targets
 - E1.1.3 Mechanism of Action of Drugs
 - E1.1.4 Drug Targets
 - E1.1.5 Contribution of Recombinant Technologies
 - E1.1.6 Operational Strategy: Docking
- **E1.2 Analytical Process**
 - E1.2.1 The Analytical Process
 - E1.2.2 Data Collection: X-Ray Crystallography
 - E1.2.3 Data Collection: NMR Spectroscopy
 - E1.2.4 Data Collection: Homology Models
 - E1.2.5 Analysis
 - E1.2.6 Design Phase
- **E1.3 Principles of Analysis**
 - E1.3.1 Analysis of the Morphology of the Active Site
 - E1.3.2 Morphology of the Active Site of a Protein Kinase
 - E1.3.3 Complexes with Ligands
 - E1.3.4 Forces That Contribute to the Binding

- E1.3.5 The Molecular Recognition Process
- E1.3.6 Electrostatic
- E1.3.7 Hydrogen Bonding
- E1.3.8 Hydrophobic
- E1.3.9 Hydrophobic Interactions
- E1.3.10 Consider Hydrophobic Interactions
- E1.3.11 Elementary Hydrophobic Interactions
- E1.3.12 Example of Hydrophobic Binding
- E1.3.13 Strengthening Hydrophobic Interactions
- E1.3.14 Hydrogen Bond Features
- E1.3.15 Proteins Capabilities in Hydrogen Bonding
- E1.3.16 Consider Hydrogen Bond Formations
- E1.3.17 Elementary Hydrogen Bond Interactions
- E1.3.18 Example of the Hydrogen Bond Binding
- E1.3.19 Electrostatic Interactions
- E1.3.20 Elementary Electrostatic Interactions
- E1.3.21 Strength of Electrostatic Interactions
- E1.3.22 Example of Electrostatic Interactions
- E1.3.23 Increase of Potency by the Formation of a Salt Bridge
- E1.3.24 OH Analog Much Less Potent

- E1.4 Example of Tight Interactions
 - E1.4.1 An Example of a Tight Ligand-Receptor Interaction
 - E1.4.2 The X-ray Structure of the Biotin/Streptavidin
 - E1.4.3 The Binding Mode of Biotin with Streptavidin (1/4)
 - E1.4.4 The Binding Mode of Biotin with Streptavidin (2/4)
 - E1.4.5 The Binding Mode of Biotin with Streptavidin (3/4)
 - E1.4.6 The Binding Mode of Biotin with Streptavidin (4/4)

- E1.5 Receptor & Ligand Flexibility
 - E1.5.1 Flexibility of the Receptor
 - E1.5.2 Flexibility of The Ligand
 - E1.5.3 Entropic Effects

- E1.6 Role of the Solvent
 - E1.6.1 Solvation and Desolvation
 - E1.6.2 The Role of the Solvent
 - E1.6.3 Relay with Water Molecules
 - E1.6.4 Relay with Several Water Molecules
 - E1.6.5 Relay with Water Molecule Having Four H-Bonds

- E1.7 Prediction of Binding Modes
 - E1.7.1 Binding Modes Predicted by Analogy
 - E1.7.2 Inversion of Binding Modes
 - E1.7.3 Inverted Binding Mode of Olomoucine
 - E1.7.4 X-Ray Structure of ATP Bound to a Protein Kinase
 - E1.7.5 Intuitive 2D Alignment for Olomoucine
 - E1.7.6 Experimental Binding Mode of Olomoucine
 - E1.7.7 Origin of the Inverted Binding Mode of Olomoucine
 - E1.7.8 Inverted Binding Mode of Methotrexate
 - E1.7.9 Intuitive 2D Alignment for Methotrexate
 - E1.7.10 Experimental Binding Mode of Methotrexate
 - E1.7.11 Origin of the Inverted Binding Mode of Methotrexate
 - E1.7.12 Binding Mode Predicted from SAR

- E1.8 Methods for Analyzing Binding
 - E1.8.1 Analyzing Ligand-Receptor Binding
 - E1.8.2 Ligand-Binding Predictions
 - E1.8.3 Visual Analyses
 - E1.8.4 Docking Analyses
 - E1.8.5 Manual Docking with Computer Graphics

- E1.8.6 Automated Methods for Docking
- E1.8.7 Calculation of Binding Energies
- E1.8.8 Free Energy Perturbation Techniques
- E1.8.9 Energies from Force Field Calculations
- E1.8.10 Correlation with Biological Activities
- E1.8.11 Energies from Scoring Functions
- E1.8.12 Limitations of Scoring Functions
- E1.8.13 Calculating Desolvation Energies
- E1.9 Conclusion
 - E1.9.1 Conclusion
- E1.10 CHAPTER QUIZZES (Available only in Teaching Package)



F. CHEMINFORMATICS

○ F1. MOLECULAR SIMILARITY

- F1.1 Introduction
 - F1.1.1 Similarity and Complementarity-Based Drug Design
 - F1.1.2 Comparing Molecules: a Central Issue in Drug Discovery
 - F1.1.3 The Molecular Similarity Principle
 - F1.1.4 Subjectivity of the Similarity Concept
 - F1.1.5 What can be Similar in Molecules?
 - F1.1.6 2D-Structure Similarity
 - F1.1.7 Shape Similarity
 - F1.1.8 Surface Physicochemical Similarity
 - F1.1.9 H-Bond Similarity
 - F1.1.10 Absence of Particular Features
 - F1.1.11 Pharmacophore Similarity
 - F1.1.12 Comparing Molecular Characteristics
 - F1.1.13 Terminology: Similarity Attributes
 - F1.1.14 Relevant Characteristics: What is Important?
 - F1.1.15 Relativity of Relevant Properties
 - F1.1.16 Interpretable Characteristics
 - F1.1.17 Global and Local Characteristics
 - F1.1.18 Maximizing Similarity: Object Alignments
 - F1.1.19 The Psychology of Similarity
 - F1.1.20 Molecular Similarity in Medicinal Chemistry Era
 - F1.1.21 Cheminformatics
- F1.2 Medicinal Chemistry Approaches Based on the Similarity Principle
 - F1.2.1 Chemical Modifications
 - F1.2.2 Bioisosteric Replacements
 - F1.2.3 Molecular Mimicry
 - F1.2.4 Mee-too-ism
 - F1.2.5 Peptidomimetics
 - F1.2.6 Lead-Like and Drug-Like Approaches
- F1.3 Similarity Searching in Database
 - F1.3.1 Exact and Substructure Searching
 - F1.3.2 Similarity Searching
 - F1.3.3 Semi-Manual Similarity Searching
 - F1.3.4 Similarity Concept and Creativity
 - F1.3.5 Output of Similarity Searching
 - F1.3.6 Broad Range of Applications
 - F1.3.7 Substructure & Similarity Searching Complementarities

- F1.3.8 General Requirements of a Method
 - F1.3.9 Make Molecules Accessible to the Computer
 - F1.3.10 Need of Methods to Measure Similarity
 - F1.3.11 Apply an Algorithm
- F1.4 Molecular Descriptors: Make Molecules Accessible to the Computer
 - F1.4.1 The Concept of "Molecular Descriptors"
 - F1.4.2 Selection of Relevant Descriptors
 - F1.4.3 High-Dimensionality Space of the Molecular Descriptors
 - F1.4.4 Example of Selection of Relevant Descriptors
 - F1.4.5 Binary and Numerical Descriptors
 - F1.4.6 Experimental and Calculated Molecular Descriptors
 - F1.4.7 Predefined vs. Algorithmically Defined Descriptors
 - F1.4.8 Possible Classification of Molecular Descriptors
- F1.5 Examples of Molecular Descriptors
 - F1.5.1 1D Descriptors: Single Numbers or Sequences
 - F1.5.2 Topological Indices
 - F1.5.3 Electrotopological Descriptors
 - F1.5.4 Linear Representations of Molecules
 - F1.5.5 2D Descriptors: Fragments and Substructures
 - F1.5.6 Spectra-Derived Descriptors
 - F1.5.7 Graph-Based Multiple Point Pharmacophores
 - F1.5.8 Reduced Graph and Feature Trees
 - F1.5.9 Ghose and Crippen Descriptors
 - F1.5.10 3D Descriptors
 - F1.5.11 Field-Based Descriptors
 - F1.5.12 Multiple-Point Pharmacophores
 - F1.5.13 Surface-Based Descriptors
 - F1.5.14 4D Chirality Descriptors
 - F1.5.15 Virtual Affinity Fingerprints
 - F1.5.16 BCUT Descriptors
- F1.6 Comparing Molecules: Similarity Coefficients
 - F1.6.1 Methods to Quantify Similarity
 - F1.6.2 Similarity Coefficients of Relevant Properties
 - F1.6.3 Binary and Distance-Based Formulas
 - F1.6.4 Distance Coefficients
 - F1.6.5 Similarity Coefficients
 - F1.6.6 Symmetry Problems in Similarity Analysis
 - F1.6.7 Symmetrical vs. Asymmetrical Similarity in Psychology
 - F1.6.8 Does the Absence of Features Indicate Similarity?
 - F1.6.9 Examples of Similarity and Distance Coefficients
 - F1.6.10 The Tanimoto Coefficient
 - F1.6.11 Dice and Cosine Similarity Coefficients
 - F1.6.12 Tversky Similarity Coefficient
 - F1.6.13 Some Common Distance Coefficients
- F1.7 Examples of Direct Use of Similarity Coefficients
 - F1.7.1 Searching Molecules with Similar Properties
 - F1.7.2 Searching Information from Similar Molecules
 - F1.7.3 Knowing a Pharmacophore, Search for Novel Molecules
 - F1.7.4 Example of a Fuzzy Pharmacophore
 - F1.7.5 Validation of Novelty
 - F1.7.6 Reducing a Virtual Library to a Practical Size
 - F1.7.7 Peptidomimetics
 - F1.7.8 Compounds that Fit the Shape of an Active Site
 - F1.7.9 Find a Synthetic Route
 - F1.7.10 Filtering Undesired Hits
 - F1.7.11 Clustering of Molecules

- **F1.8 Development of Computational Models**
 - F1.8.1 Development of a Structure-Property Model
 - F1.8.2 Deriving Knowledge from Distances and Properties
 - F1.8.3 Molecules in the Space of the Descriptors
 - F1.8.4 QSAR and 3D-QSAR
 - F1.8.5 QSPR - Quantitative Structure-Property Relationships
 - F1.8.6 Intelligent Machine Learning Models
 - F1.8.7 Binary Kernel Discrimination
 - F1.8.8 Artificial Neural Networks
 - F1.8.9 Support Vector Machines (SVMs)
 - F1.8.10 Binary QSAR and Naive Bayes Classifier
 - F1.8.11 Rule-Based Approaches
 - F1.8.12 Decision Trees

- **F1.9 Practical Applications of Structure-Property Models**
 - F1.9.1 Example of a 3D-QSAR Model
 - F1.9.2 Molecular Similarity: Models of ADME/Tox Predictions
 - F1.9.3 'A' - Absorption: Does a Drug Work Orally?
 - F1.9.4 'D' - Distribution: Where Does the Drug Go in the Body?
 - F1.9.5 'M' - Metabolism: The Drug's Fate
 - F1.9.6 'E' - Elimination: The Drug Says Good-Bye
 - F1.9.7 'Tox' - Toxicity: Side-Effects
 - F1.9.8 Prediction of Solubility
 - F1.9.9 Prediction of Melting Points

- **F1.10 Important Properties of Molecular Descriptors and Similarity Coefficients**
 - F1.10.1 Neighborhood Behavior
 - F1.10.2 Back-Projectability
 - F1.10.3 Validation and Information Content of Descriptors
 - F1.10.4 Properties of Binary Fingerprints
 - F1.10.5 Folding of Fingerprints
 - F1.10.6 The Concept of Binning
 - F1.10.7 The Concept of "Fuzzy" Descriptors
 - F1.10.8 Size-Bias of the Tanimoto Similarity Coefficient
 - F1.10.9 Size-Bias: Favoring Large Molecules
 - F1.10.10 2D vs. 3D Descriptors

- **F1.11 Choice of the Best Method for Calculating Similarity Coefficients**
 - F1.11.1 Unique Content of Each Similarity Coefficient?
 - F1.11.2 Clustering Similarity Coefficients
 - F1.11.3 Consensus Scoring: Asking a Panel of Experts
 - F1.11.4 Why Does Consensus Scoring Improve the Results?
 - F1.11.5 What Algorithms Exist for Consensus Scoring?

- **F1.12 Limitations of the Concept of "Molecular Similarity"**
 - F1.12.1 Limitation of Ligand-Based Approaches
 - F1.12.2 Example of Ligand-Based Approach Limitation
 - F1.12.3 Limitation Due to Extrapolations
 - F1.12.4 Limitation Due to Pitfalls in interpolations
 - F1.12.5 Principle of Continuity
 - F1.12.6 Discontinuity in Molecular Recognition
 - F1.12.7 Bumps
 - F1.12.8 Ligand Conformational Change
 - F1.12.9 Receptor Conformational Changes
 - F1.12.10 Flip in Binding Mode
 - F1.12.11 Discontinuity in Ligand Property
 - F1.12.12 pKa
 - F1.12.13 LogP
 - F1.12.14 Discontinuity in the Function of the Receptor

- F1.13 Conclusions
 - F1.13.1 How Does "Molecular Similarity" Fare Today?
 - F1.13.2 How Many Chances of Being Active?
 - F1.13.3 Economic Rationale of Similarity-Based Methods
 - F1.13.4 Perspectives
- F1.14 CHAPTER QUIZZES (Available only in Teaching Package)



G. LIGAND-BASED DESIGN

○ G1. PRINCIPLES IN PHARMACOPHORE ELUCIDATION

- G1.1 Introduction
 - G1.1.1 Pharmacophore-Based Drug Design
 - G1.1.2 Operational Strategy: Molecular Mimicry
 - G1.1.3 Analogy with Keys
 - G1.1.4 Active Molecules are Complicated Keys
 - G1.1.5 Definition of a Pharmacophore
- G1.2 Analytical Process
 - G1.2.1 The Analytical Process
 - G1.2.2 Data Collection Stage
 - G1.2.3 Analysis Stage
 - G1.2.4 Design Phase
- G1.3 Simple Case
 - G1.3.1 Introduction with a Simple Case
 - G1.3.2 Molecular Similarity
 - G1.3.3 Difficulty to Identify Common 3D Features
 - G1.3.4 Superimpositions
 - G1.3.5 Goal of Superimposition Procedures
 - G1.3.6 Summary of the Example
 - G1.3.7 Superimposition Technique
 - G1.3.8 Superimposition Technique: Results
 - G1.3.9 Dummy Atoms
- G1.4 Typical Example
 - G1.4.1 A More Typical Example
 - G1.4.2 Identification of the Bioactive Conformation
 - G1.4.3 Conformers of Molecule A
 - G1.4.4 Conformers of Molecule B
 - G1.4.5 Bioactive Conformation: Geometry
 - G1.4.6 Bioactive Conformation: Energy
 - G1.4.7 Reduction of the Complexity
 - G1.4.8 Bioactive Conformations Must be Superimposable
 - G1.4.9 Systematic Superimposition of Conformers
 - G1.4.10 Results with High Informational Content
 - G1.4.11 Summary
- G1.5 Complexity Levels
 - G1.5.1 Rigid and Flexible Molecules
 - G1.5.2 Bioactive Conformation of GABA
 - G1.5.3 Methyl Analog of GABA
 - G1.5.4 Muscimol is a GABA Agonist
 - G1.5.5 THIP is a GABA Agonist
 - G1.5.6 The Deduced Bioactive Conformation of GABA
 - G1.5.7 Superimposition in the Space of Properties

- G1.5.8 Example of Superimposition in the Space of Properties
- G1.5.9 Alignment Based on the 2D Formulas
- G1.5.10 Different Electrostatic Distribution in 2D Alignment
- G1.5.11 Alignment Based on 3D Structures of Complexes
- G1.5.12 Correct Alignment: Similar Electrostatic Distribution

- **G1.6 Principles of Analysis**
 - G1.6.1 Complexity of Analyses (1/3)
 - G1.6.2 Complexity of Analyses (2/3)
 - G1.6.3 Complexity of Analyses (3/3)
 - G1.6.4 Six Rules for Analyses
 - G1.6.5 Common Structural Features: Rule 1
 - G1.6.6 Multiple Hypotheses: Rule 2
 - G1.6.7 Inactive Molecules: Rule 3
 - G1.6.8 Closely Related Molecules: Rule 4
 - G1.6.9 Molecules With No Common Features: Rule 5
 - G1.6.10 Mapping the Receptor: Rule 6

- **G1.7 Conformational Control**
 - G1.7.1 Control of the Molecular Geometries
 - G1.7.2 3D Considerations
 - G1.7.3 Cimetidine Example
 - G1.7.4 Folded Conformation of Cimetidine
 - G1.7.5 2D Considerations
 - G1.7.6 Example
 - G1.7.7 3D Superimpositions Must be Realistic
 - G1.7.8 Misuse of Structural Information

- **G1.8 Managing Hypotheses**
 - G1.8.1 Initial Requirements
 - G1.8.2 Same Mechanism of Action?
 - G1.8.3 Chlorpromazine Example
 - G1.8.4 Tracking & Reconsidering Hypotheses
 - G1.8.5 Incorrect Hypotheses
 - G1.8.6 Example 1
 - G1.8.7 Example 2
 - G1.8.8 Multiple Pharmacophore Hypotheses: Example
 - G1.8.9 Dopamine Agonists: Where is the Pharmacophore ?
 - G1.8.10 Pharmacophore Model A
 - G1.8.11 Pharmacophore Model B
 - G1.8.12 Each Model Gave Good Results
 - G1.8.13 Poor Initial Data: Too Many Hypotheses
 - G1.8.14 Validating Hypotheses by Chemical Syntheses
 - G1.8.15 X-Ray Analyses
 - G1.8.16 Rigid Analogs Synthesized
 - G1.8.17 Browser of Dopamine D2 Agents

- **G1.9 Receptor Mapping**
 - G1.9.1 The Role of Inactive Molecules
 - G1.9.2 Inactive Analog of Nifedipine
 - G1.9.3 Rearrangement of the Bioactive Conformation
 - G1.9.4 Two Boat Conformations of Dihydropyridine Ring
 - G1.9.5 Preferred Conformation of Nifedipine
 - G1.9.6 Origin of the Inactivity Methyl-4 Nifedipine
 - G1.9.7 Judging with Discernment
 - G1.9.8 Good Understanding of Conformational Aspects
 - G1.9.9 The Active Analog Principle
 - G1.9.10 Receptor Essential Volume
 - G1.9.11 Volumes with Favorable or with Bad Interactions
 - G1.9.12 Active Analog Approach Browser

- G1.9.13 Example of Receptor Mapping
 - G1.9.14 Receptor Map of Nicotinic Agonists
- G1.10 Two Generations of Pharmacophores
 - G1.10.1 The Two Generations of Pharmacophores
 - G1.10.2 The First Generation of Pharmacophores
 - G1.10.3 Mianserin Pharmacophore in 3D
 - G1.10.4 The Second Generation of Pharmacophores
 - G1.10.5 Future
- G1.11 Summary
 - G1.11.1 Pharmacophore-Based Drug Design Summary
- G1.12 CHAPTER QUIZZES (Available only in Teaching Package)



H. QSAR AND CHEMOMETRICS

○ H1. QSAR: PRINCIPLES AND METHODS

- H1.1 Introduction to QSAR
 - H1.1.1 Molecular Structure and Molecular Properties
 - H1.1.2 Structure-Property Relationships: Example 1
 - H1.1.3 Structure-Property Relationships: Example 2
 - H1.1.4 Structure-Property Relationships: Example 3
 - H1.1.5 What is QSAR?
 - H1.1.6 What is QSPR?
 - H1.1.7 Focus on a Single Property at a Time
 - H1.1.8 Molecular Descriptors
 - H1.1.9 Examples of Molecular Descriptors
 - H1.1.10 The QSAR Equations
 - H1.1.11 Types of Molecular Descriptors
 - H1.1.12 Molecular Descriptors: 1D
 - H1.1.13 Molecular Descriptors: 2D
 - H1.1.14 Molecular Descriptors: 3D
 - H1.1.15 A Multitude of Molecular Descriptors
 - H1.1.16 Biologically Relevant Descriptors
 - H1.1.17 Application of QSAR
 - H1.1.18 Understanding Structure-Activity Relationships
 - H1.1.19 Designing Compounds with Improved Activities
 - H1.1.20 Reducing a Virtual Library to a Practical Size
- H1.2 The Foundations of QSAR
 - H1.2.1 Birth of QSAR
 - H1.2.2 The Foundations of QSAR
 - H1.2.3 The Hammett Contribution
 - H1.2.4 Dissociation Constants of Substituted Benzoic Acids
 - H1.2.5 Dissociation of Substituted Phenylacetic Acids
 - H1.2.6 Linear Free Energy Relationship
 - H1.2.7 The Hammett Equation
 - H1.2.8 The Meaning of ρ
 - H1.2.9 The Meaning of σ
 - H1.2.10 Examples of σ Constants
 - H1.2.11 Predicting the pKa of Benzoic Acid Compounds
 - H1.2.12 Hansch Contribution
 - H1.2.13 The Importance of Lipophilicity
 - H1.2.14 LogP is a Measure of Compounds Lipophilicity
 - H1.2.15 Correlation of LogP with Biological Activities

- H1.2.16 Example of Correlation with LogP
- H1.2.17 Improvements of the Initial Model
- H1.2.18 The π Descriptor
- H1.2.19 The MR Descriptor
- H1.2.20 The Taft Descriptor (ES)
- H1.2.21 Meaning of Parabolic Dependence on LogP
- H1.2.22 The Free-Wilson Analysis
- H1.2.23 Indicator Variables and Substituent Weights
- H1.2.24 Free-Wilson Structural Matrix
- H1.2.25 Example of Structural Matrix
- H1.2.26 Example of Free-Wilson Equation
- H1.2.27 Predictability of the Model
- H1.2.28 Understanding the Molecular Determinants

- H1.3 Design of a QSAR Model
 - H1.3.1 Embarking on the Design of a QSAR Model
 - H1.3.2 The Four Steps
 - H1.3.3 An Iterative Process

- H1.4 Compounds Selection: Step 1
 - H1.4.1 Compounds Selection
 - H1.4.2 Predictions by Interpolation
 - H1.4.3 Example of Extrapolative Model
 - H1.4.4 Identification of Outliers
 - H1.4.5 Biological Activities in Terms of Log 1/C

- H1.5 Descriptors Selection: Step 2
 - H1.5.1 Descriptors Selection
 - H1.5.2 Methods for Selecting Relevant Descriptors
 - H1.5.3 Manual Selection of Descriptors
 - H1.5.4 Automated Selection of Descriptors
 - H1.5.5 Systematic Combination of Descriptors
 - H1.5.6 Methods for Selecting a Subset of Descriptor
 - H1.5.7 Forward Selection
 - H1.5.8 Backward Elimination
 - H1.5.9 Stepwise Regression
 - H1.5.10 Scaling Descriptors
 - H1.5.11 Correlation Between Descriptors
 - H1.5.12 Example of Correlated Descriptors
 - H1.5.13 Solution to the Problem of Correlated Descriptors
 - H1.5.14 The Holy Grail in QSAR

- H1.6 Deriving the Equation: Step 3
 - H1.6.1 Deriving The QSAR Equation
 - H1.6.2 The Starting Point: The Study Table
 - H1.6.3 Graphical Analysis of the Data
 - H1.6.4 Choice of the Mathematical Equation
 - H1.6.5 Complexity Levels and Data Overfitting
 - H1.6.6 Mathematics are Very (too) Powerful
 - H1.6.7 Illustration with an Example
 - H1.6.8 A Simple Model
 - H1.6.9 A Complex Model
 - H1.6.10 Comparing the Two Models
 - H1.6.11 Predictive Power of the Simple Model
 - H1.6.12 Predictive Power of the Complex Model
 - H1.6.13 Complexity Dictated by Predictability of the Model
 - H1.6.14 Single Linear Equation: Mathematical Outline
 - H1.6.15 Calculating b_0 and b_1
 - H1.6.16 Multiple Linear Regression: Mathematical Outline
 - H1.6.17 Example: MLR vs. Single Linear Models

- H1.6.18 The Mathematics of MLR: a Single Sample
- H1.6.19 The Mathematics of MLR: Many Molecules
- H1.6.20 The Solution of MLR
- H1.6.21 Analysis of the MLR Equation
- H1.6.22 Non-Linear Equations
- H1.6.23 Example of Non-Linear Model
- H1.6.24 Typical Non-Linear Equations
- **H1.7 Validating the Model: Step 4**
 - H1.7.1 Tools for Assessing the Quality of a Model
 - H1.7.2 Predictive and non-Predictive Models
 - H1.7.3 The Standard Deviation
 - H1.7.4 Correlation Index r^2
 - H1.7.5 The Mathematics of r^2
 - H1.7.6 TSS, the Total Variance
 - H1.7.7 RSS, the Explained Variance
 - H1.7.8 t-test for Single Descriptors and Significance of r^2
 - H1.7.9 Shape of t-distribution and Number of Molecules
 - H1.7.10 Student's t-test Procedure
 - H1.7.11 F-test for Assessing the Significance of r^2
 - H1.7.12 Performing the F-test
 - H1.7.13 F-test Procedure
 - H1.7.14 Assessing the Predictive Power of a Model
 - H1.7.15 The Test Set Method
 - H1.7.16 The Cross Validation Method
 - H1.7.17 Limits of the Cross Validation Method
 - H1.7.18 The Predictive Index Q^2
 - H1.7.19 Summary
- **H1.8 CHAPTER QUIZZES (Available only in Teaching Package)**



I. MOLECULAR BASIS OF DRUGS

○ **II. MOLECULAR GEOMETRY**

- **II.1 2D/3D**
 - II.1.1 Molecules Considered as 2D Structures
 - II.1.2 The Three-Dimensional Shape of a Molecule
 - II.1.3 2D and 3D Representations
 - II.1.4 A Molecule: An Assembly of Atoms in 3D
 - II.1.5 Molecular Lego
 - II.1.6 Molecular Fragments for Constructing Molecules
- **II.2 Conformers**
 - II.2.1 A Molecule is a Flexible Entity
 - II.2.2 Conformation Definition
 - II.2.3 Example of Conformations of a Molecule
 - II.2.4 Bioactive Conformation
- **II.3 Torsion Angles**
 - II.3.1 Interconversion Between Conformers
 - II.3.2 How Do Interconversions Occur?
 - II.3.3 Definition of the Conformers of a Molecule
 - II.3.4 The Torsion Angle Concept
 - II.3.5 Definition of Torsion Angles
 - II.3.6 Monitoring Torsion Angles
 - II.3.7 Newman Projections and Torsion Angles

- 11.3.8 Convention for the Sign of Torsion Angles
 - 11.3.9 Ring Conformations
 - 11.4 Conformational Complexity
 - 11.4.1 Rigid and Flexible Molecules
 - 11.4.2 Codeine and Fenoxedil
 - 11.4.3 Monitoring Torsion Angle Combinations
 - 11.4.4 Conformational Explosion
 - 11.5 Ratio of Conformers
 - 11.5.1 Mixtures of Conformers
 - 11.5.2 Ratio of Conformers and Population
 - 11.6 CHAPTER QUIZZES (Available only in Teaching Package)
-

○ 12. MOLECULAR PROPERTIES

- 12.1 Introduction
 - 12.1.1 Properties of a Molecule
 - 12.1.2 Average of a Conformational-Dependent Property
 - 12.1.3 Importance of the 3D Molecular Geometries
 - 12.2 Biological Properties
 - 12.2.1 Biological Properties of Proteins
 - 12.2.2 Biological Properties of Chiral Analgesics
 - 12.3 Physical Properties
 - 12.3.1 Physical Properties
 - 12.3.2 Calculation of Other Physical Properties
 - 12.4 Chemical Properties
 - 12.4.1 Chemical Properties
 - 12.4.2 Enolization of Keto-3 Steroids
 - 12.4.3 Relative Stability of Isomers
 - 12.4.4 Relative Stability of the two Isomers of Trans-Octalin
 - 12.4.5 Geometrical Preference Explains Enolization
 - 12.4.6 Reactivity of Alkyl Halides
 - 12.4.7 SN2 Mechanism
 - 12.4.8 E2 Elimination Mechanism
 - 12.4.9 Molecular Geometries and Chemical Properties
 - 12.5 Many Properties
 - 12.5.1 Many Properties of a Molecule
 - 12.6 CHAPTER QUIZZES (Available only in Teaching Package)
-

○ 13. STEREOCHEMISTRY

- 13.1 Introduction
 - 13.1.1 Introduction on Stereochemistry
 - 13.1.2 Bond Lengths
 - 13.1.3 Bond Multiplicity
 - 13.1.4 Atom Size
 - 13.1.5 Electronegativity
 - 13.1.6 Hybridization
 - 13.1.7 Bond Angles
 - 13.1.8 Thorpe-Ingold Effect

- 13.1.9 Torsion Angles
- 13.1.10 Torsion Angle Sign Convention
- 13.1.11 Examples of Torsion Angles
- 13.1.12 Torsion Angle Descriptor (sp³-sp³)
- 13.1.13 Torsion Angle Descriptor (sp²-sp³)
- 13.2 Chirality
 - 13.2.1 Chirality
 - 13.2.2 Example 1
 - 13.2.3 Example 2
 - 13.2.4 Chirality Descriptor: Optical Rotation
 - 13.2.5 Chirality Nomenclature
 - 13.2.6 The Order of Priority (1/5)
 - 13.2.7 The Order of Priority (2/5)
 - 13.2.8 The Order of Priority (3/5)
 - 13.2.9 The Order of Priority (4/5)
 - 13.2.10 The Order of Priority (5/5)
 - 13.2.11 Examples of R/S Assignments (1/4)
 - 13.2.12 Examples of R/S Assignments (2/4)
 - 13.2.13 Examples of R/S Assignments (3/4)
 - 13.2.14 Examples of R/S Assignments (4/4)
 - 13.2.15 The Newman Projection
 - 13.2.16 The Fischer Projection (1/3)
 - 13.2.17 The Fischer Projection (2/3)
 - 13.2.18 The Fischer Projection (3/3)
 - 13.2.19 Chirality: D/L
 - 13.2.20 D-alanine
 - 13.2.21 L-alanine
 - 13.2.22 Chirality: Erythro/Threo
 - 13.2.23 Threo
 - 13.2.24 Erythro
 - 13.2.25 Other Examples of Chiral Molecules: Example 1
 - 13.2.26 Example 2 of Chiral Molecule
 - 13.2.27 Example 3 of Chiral Molecule
 - 13.2.28 Example 4 of Chiral Molecule
 - 13.2.29 Example 5 of Chiral Molecule
 - 13.2.30 Example 6 of Chiral Molecule
- 13.3 Double Bonds
 - 13.3.1 Cis-Trans Stereochemistry of Double Bonds
 - 13.3.2 E/Z Stereochemistry of Double Bonds
 - 13.3.3 s-cis/s-trans Conformations
 - 13.3.4 Re/Si Nomenclature of the Faces of Double Bonds
- 13.4 Rings
 - 13.4.1 Rings
 - 13.4.2 Chair
 - 13.4.3 Boat
 - 13.4.4 Twist Boat
 - 13.4.5 Crown
 - 13.4.6 Rings: Axial and Equatorial Orientations
- 13.5 Symmetry
 - 13.5.1 Introduction on Symmetry Operations
 - 13.5.2 Symmetry C₂
 - 13.5.3 Symmetry C₃
 - 13.5.4 Symmetry Sigma
 - 13.5.5 Inversion (i)
 - 13.5.6 Example of Inversion
 - 13.5.7 Rotatory Reflection (S_n)



○ 14. MOLECULAR ENERGIES

■ 14.1 Introduction

- 14.1.1 Internal Energy of a Molecule
- 14.1.2 Internal Energy Associated to a Conformation
- 14.1.3 Transition State
- 14.1.4 Potential Surface
- 14.1.5 Thermodynamics & Kinetics

■ 14.2 Thermodynamics

- 14.2.1 Thermodynamics: Conformer Populations
- 14.2.2 Thermodynamics: Boltzmann Equation
- 14.2.3 Boltzmann Population Analysis for Two Conformers
- 14.2.4 Boltzmann Population Analysis for 3 Conformers
- 14.2.5 Thermodynamics: Cyclohexane Example
- 14.2.6 Populations of Twisted-Boat and Chair Conformers
- 14.2.7 Thermodynamics: Methylcyclohexane Example

■ 14.3 Kinetics

- 14.3.1 Kinetics
- 14.3.2 Kinetics: Arrhenius Equation
- 14.3.3 Kinetics: Arrhenius Graph
- 14.3.4 Kinetics Ethane Example
- 14.3.5 Torsional Barrier in Ethane
- 14.3.6 Kinetics Cyclohexane Example
- 14.3.7 Interconversion Barrier in Cyclohexane
- 14.3.8 Kinetics Amide Bond Example
- 14.3.9 Amide Barrier Crossed Every 10 Seconds

■ 14.4 Molecular Modeling

- 14.4.1 Molecular Modeling
- 14.4.2 Example of Kinetic or Thermodynamic Control
- 14.4.3 Interconversion Between the Two Forms
- 14.4.4 Lowering the Energy of the Transition State
- 14.4.5 Interconversion Between the Two Forms
- 14.4.6 Raising the Energy of the Transition State
- 14.4.7 Interconversion Between the Two Forms
- 14.4.8 Modifying Conformers Populations
- 14.4.9 Repulsions More Important in the Boat Form
- 14.4.10 Tropane is Found Only in a Chair Conformation
- 14.4.11 Example of Atropisomerism
- 14.4.12 Molecular Energies: The Key of Molecular Modeling

■ 14.5 Modeling in Drug Design

- 14.5.1 Molecular Modeling in Drug Design
- 14.5.2 Importance of Energies: the Morphinan Example
- 14.5.3 Morphinan and D-nor Morphinan Alignment
- 14.5.4 Conformational Analysis of Morphinan
- 14.5.5 Conformational Analysis of D-nor Morphinan
- 14.5.6 A Rationale for Explaining the Activities Observed
- 14.5.7 Morphinan: Validation and Design
- 14.5.8 Preferred Conformer of Active Enantiomer
- 14.5.9 Preferred Conformer of Inactive Enantiomer
- 14.5.10 Restoring Activities to the Inactive Analog?
- 14.5.11 Morphinan Browser
- 14.5.12 What We Can Learn From The Morphinan Example

- I4.6 How to Calculate Energies
 - I4.6.1 The Need of Tools for Calculating Energies
 - I4.6.2 Two Methods for Calculating Energies
- I4.7 Quantum Mechanics
 - I4.7.1 Calculation of Energies by the Schrodinger Equation
 - I4.7.2 Ab-Initio and Semi-empirical Calculations
 - I4.7.3 Calculation of Energies
 - I4.7.4 The Density Function Theory
 - I4.7.5 The Choice of a Method
- I4.8 Molecular Mechanics
 - I4.8.1 Molecular Mechanics
 - I4.8.2 Force-Field
 - I4.8.3 Force Field Components
 - I4.8.4 Bond Lengths: Stretching Contributions
 - I4.8.5 Function
 - I4.8.6 Examples of Elementary Stretching Contributions
 - I4.8.7 Bond Angles: Bending Contributions
 - I4.8.8 Function
 - I4.8.9 Examples of Elementary Bending Contributions
 - I4.8.10 Torsion Angles: Torsional Contributions
 - I4.8.11 Function
 - I4.8.12 Examples of Elementary Torsional Contributions
 - I4.8.13 Van der Waals Interactions
 - I4.8.14 Function
 - I4.8.15 Examples of Elementary Van der Waals
 - I4.8.16 Electrostatic Dipolar Contributions
 - I4.8.17 Function
 - I4.8.18 Examples of Elementary Electrostatic Contributions
 - I4.8.19 Hydrogen Bond Energy Contributions
 - I4.8.20 Function
 - I4.8.21 Examples of Elementary Hydrogen Bond Contributions
 - I4.8.22 Total Energy in a Force Field Calculation
 - I4.8.23 Main Force Fields
 - I4.8.24 What One Should Remember
 - I4.8.25 Relative Energies
- I4.9 CHAPTER QUIZZES (Available only in Teaching Package)



○ I5. CONFORMATIONAL ANALYSIS

- I5.1 Introduction
 - I5.1.1 Geometries, Energies and Conformational Analysis
 - I5.1.2 Energy Profile: a Global Information
 - I5.1.3 Definition of Conformational Analysis
- I5.2 Potential Surface
 - I5.2.1 Conformational Potential Surface: One Rotation
 - I5.2.2 Conformational Potential Surface: Two Rotations
 - I5.2.3 Energy Profile Viewed from the Top
 - I5.2.4 Energy Profile Viewed as Contour Lines
 - I5.2.5 Conformational Potential Surface
 - I5.2.6 Special Forms
 - I5.2.7 Interconversion Between Conformers
 - I5.2.8 Energy Barriers
 - I5.2.9 Interconversion Pathway

- **I5.3 Conformational Analysis**
 - I5.3.1 Conformational Analysis Principles
 - I5.3.2 Systematic Scanning of All Potential Surfaces
 - I5.3.3 Systematic Scanning is Time Consuming
 - I5.3.4 How to Reduce Conformational Search?
 - I5.3.5 One Conformer Represents a Whole Family
 - I5.3.6 Working with a Set of Representative Conformers
 - I5.3.7 Sildenafil Example
 - I5.3.8 Family Representatives: Small Rings
 - I5.3.9 Family Representatives: Acyclic Bonds
 - I5.3.10 Consequence: Minimization Treatments
 - I5.3.11 Example: Analysis of Elementary Fragments
 - I5.3.12 Example: Generation of Representative Conformers
 - I5.3.13 Example: Results of Conformational Analysis
 - I5.3.14 Conformational Analysis Principles: Summary
- **I5.4 Minimizations**
 - I5.4.1 Definition of the Minimization of a Conformer
 - I5.4.2 Improved Geometries and Good Energies
 - I5.4.3 The Minimization Treatment
 - I5.4.4 How Does Minimization Works?
 - I5.4.5 Minimization Methods
 - I5.4.6 Many Variables Are Minimized
 - I5.4.7 Minimization is a Time-Consuming Treatment
- **I5.5 Examples of Minimization**
 - I5.5.1 Minimization with Stretching Strain
 - I5.5.2 Minimization with Bending Strain
 - I5.5.3 Minimization with Torsional Strain
 - I5.5.4 Minimization with Van der Waals Strain
 - I5.5.5 Minimization with Electrostatic Component
 - I5.5.6 Minimization with Hydrogen Bond Component
 - I5.5.7 Typical Minimization Example
 - I5.5.8 Distribution of Energy Strain
- **I5.6 Conformational Analysis in Drug Design**
 - I5.6.1 Conformational Analysis in Drug Design
 - I5.6.2 Energy of the Bioactive Form
 - I5.6.3 Low Energy of the Bioactive Conformation
 - I5.6.4 Geometry of the Bioactive Conformation
 - I5.6.5 The Experienced Molecular Modeler
 - I5.6.6 Common Errors Made with Minimization
 - I5.6.7 Example 1
 - I5.6.8 Example 2
- **I5.7 Molecular Dynamics**
 - I5.7.1 Molecular Dynamics
 - I5.7.2 Theoretical Basis of Molecular Dynamic Calculations
 - I5.7.3 Local Minima and Global Minimum
 - I5.7.4 Simulated Annealing, a Special Type of Dynamics
 - I5.7.5 Coherency of Molecular Motions
 - I5.7.6 A Typical Molecular Dynamics Run
- **I5.8 CHAPTER QUIZZES (Available only in Teaching Package)**



- **I6. MOLECULAR GRAPHICS**

- **I6.1 Introduction**

- 16.1.1 Importance of Molecular Graphics
- 16.1.2 Almost Science Fiction
- 16.1.3 History of Molecular Visualizations
- 16.1.4 [1975-1978](#)
- 16.1.5 [1978-1980](#)
- 16.1.6 [1980-1995](#)
- 16.1.7 1995-now
- 16.1.8 Commercially Available Molecular Kits
- 16.1.9 Progress in Graphical Hardware and Algorithms
- 16.1.10 Algorithm 1
- 16.1.11 Algorithm 2
- 16.1.12 Molecular Graphics Functions
- **16.2 3D Perception**
 - 16.2.1 The Perception of the Third Dimension
 - 16.2.2 From 3D Coordinates to Screen Coordinates
 - 16.2.3 2D Projection is Not Sufficient
 - 16.2.4 Real Time Manipulation
 - 16.2.5 Depth Cueing
 - 16.2.6 Perspective
 - 16.2.7 Stereo
 - 16.2.8 Hardware Stereo
- **16.3 Visualization**
 - 16.3.1 3D Representation of Small Molecules
 - 16.3.2 Line
 - 16.3.3 Stick
 - 16.3.4 Ball & Stick
 - 16.3.5 CPK
 - 16.3.6 Quality of Rendering
 - 16.3.7 Atomic Color-Code Convention
 - 16.3.8 Coloring Molecules or Sets of Atoms
 - 16.3.9 By Atom-type
 - 16.3.10 By Molecule
 - 16.3.11 By Color
 - 16.3.12 By Properties
 - 16.3.13 Labeling Functionalities
 - 16.3.14 Atom Labels
 - 16.3.15 Atom Numbering
 - 16.3.16 Proteins Representation
 - 16.3.17 Carbon Alpha
 - 16.3.18 Ribbon Representation
 - 16.3.19 Ribbon Types
 - 16.3.20 Visualization of Protein Properties
- **16.4 Editing & Manipulation**
 - 16.4.1 Structure Manipulation & Editing
 - 16.4.2 Add Atoms Function
 - 16.4.3 Delete Atoms Function
 - 16.4.4 Fuse Atoms Function
 - 16.4.5 Connect atoms Function
 - 16.4.6 3D Molecular Constructions
 - 16.4.7 Real-Time Rotations, Translations and Zoom
 - 16.4.8 Translations
 - 16.4.9 Rotations
 - 16.4.10 Zoom
 - 16.4.11 Control of Torsion Angles
 - 16.4.12 Slab and Clip
- **16.5 Surfaces & Volumes**

- 16.5.1 Concept and Definition of Molecular Surfaces
- 16.5.2 Van der Waals
- 16.5.3 Solvent
- 16.5.4 Connolly
- 16.5.5 Surface Types
- 16.5.6 Normal
- 16.5.7 Transparent
- 16.5.8 Dots
- 16.5.9 Visualization of Properties on Molecular Surfaces
- 16.5.10 Color Coded
- 16.5.11 Visualization of Properties on Molecular Surfaces
- 16.5.12 The Visualization of Volumes
- 16.5.13 Mathematical Boolean Operations with Volumes
- **16.6 Visualizing Interactions**
 - 16.6.1 Visualization of Hydrogen Bonds
 - 16.6.2 Visualization of Molecular Bumps
 - 16.6.3 Surface Representations for Bump Analyses
 - 16.6.4 Complementary Surface Properties
 - 16.6.5 Electrostatic Potentials
 - 16.6.6 Lipophilicity Potentials
 - 16.6.7 Visualization of Intramolecular Interaction
 - 16.6.8 Schematic Complex Interaction
 - 16.6.9 Visualization of a Complex Cavity
 - 16.6.10 Overview of the Entire Complex
 - 16.6.11 Results of Quantum Mechanical Calculations
- **16.7 CHAPTER QUIZZES (Available only in Teaching Package)**



○ 17. SELECTED EXAMPLES IN 3D ANALYSIS

- **17.1 Conformational Analysis**
 - 17.1.1 Ethane
 - 17.1.2 n-Butane
 - 17.1.3 1-Butene
 - 17.1.4 Butadiene
 - 17.1.5 Amide
 - 17.1.6 Cyclohexane
- **17.2 Conjugated Systems**
 - 17.2.1 Butadiene
 - 17.2.2 Pentenone
 - 17.2.3 Dipyrrole
 - 17.2.4 Biphenyl
 - 17.2.5 Atropisomerism of Biphenyls
 - 17.2.6 Binaphthyl
- **17.3 Aromatic Systems**
 - 17.3.1 Planarity of Polyaromatic Systems
 - 17.3.2 Distorted Naphthalene
 - 17.3.3 Annelated Polyaromatic Benzenes
 - 17.3.4 Fusing Another Ring
 - 17.3.5 Fusing Again Another Ring
 - 17.3.6 Continue to Fuse Additional Rings
- **17.4 Cyclic Systems**
 - 17.4.1 Why Substituents Prefer to be Equatorial?
 - 17.4.2 Mono-Substituted Cyclohexanes

- I7.4.3 t-Bu
 - I7.4.4 Phenyl
 - I7.4.5 Methyl
 - I7.4.6 Hydroxy
 - I7.4.7 Example of Preferred Axial Conformer
 - I7.4.8 Di-Methyl-1,2-Cyclohexane
 - I7.4.9 Trans
 - I7.4.10 Cis
 - I7.4.11 Di-Methyl-1,3-Cyclohexane
 - I7.4.12 Trans
 - I7.4.13 Cis
 - I7.4.14 Di-Methyl-1,4-Cyclohexane
 - I7.4.15 Trans
 - I7.4.16 Cis
 - I7.4.17 Trans 1,3-Di-t-Butyl-Cyclohexane
 - I7.4.18 Chloro-2 Cyclohexanone
- I7.5 Other Systems
 - I7.5.1 Decalins
 - I7.5.2 Cis-decalin
 - I7.5.3 Methyl-Cis-decalin
 - I7.5.4 Trans-decalin
 - I7.5.5 Interactions of Aromatic Rings
 - I7.5.6 Interactions Revealed by X-Ray Crystallography
 - I7.5.7 Two Major Types of Aromatic Interactions
 - I7.5.8 Overview of Possible Interactions
 - I7.5.9 Geometry of Ester Groups
 - I7.5.10 Cyclic Ester
 - I7.5.11 Geometry of Amide Groups
 - I7.5.12 Substituted Amide
 - I7.5.13 Cyclic Amide



J. GENERAL TOPICS

○ J1. GENERAL INTRODUCTION TO DRUGS

- J1.1 What is a Drug
 - J1.1.1 What is a Drug?
 - J1.1.2 Improvement of Life Expectancy
 - J1.1.3 Origin of Active Principles
 - J1.1.4 Drug Formulation
 - J1.1.5 Multiple Names of Drugs
 - J1.1.6 Example of Multiple Names of a Drug
 - J1.1.7 Requirements for the Ideal Drug
 - J1.1.8 Safety
 - J1.1.9 Properties
 - J1.1.10 Compliance
 - J1.1.11 Pharmacology
 - J1.1.12 Metabolism and ADME
 - J1.1.13 Side Effects and Toxicity
- J1.2 The Pharmaceutical Industry
 - J1.2.1 Drug Discovery and Development, a Long Process
 - J1.2.2 Drug Discovery and Drug Development
 - J1.2.3 One Million Studied for One to Reach the Market
 - J1.2.4 Pharmaceutical R&D, a High-Risk Undertaking

- J1.2.5 The Time of Developing a New Drug
- J1.2.6 The Cost of Developing a New Drug
- J1.2.7 Reasons for Termination of Development

■ J1.3 Industry Focus Area


- J1.3.1 Industry Focus Areas and Examples of Useful Drugs
- J1.3.2 Cardiovascular System (CVS)
- J1.3.3 Antiarrhythmics
- J1.3.4 Antihypertensive
- J1.3.5 Vasodilatation
- J1.3.6 Anticoagulants
- J1.3.7 Antihyperlipidemic
- J1.3.8 Anti-infective Agents
- J1.3.9 Antibiotics
- J1.3.10 Antiviral
- J1.3.11 Antifungals
- J1.3.12 Antimalarias
- J1.3.13 Antituberculosis
- J1.3.14 Central Nervous System (CNS) Agents
- J1.3.15 Antipsychotics
- J1.3.16 Cholinergic
- J1.3.17 Parkinsonians
- J1.3.18 Anticonvulsants
- J1.3.19 Antidepressants
- J1.3.20 Tranquilizers
- J1.3.21 Adrenergic
- J1.3.22 Gastro-Intestinal Drugs
- J1.3.23 Antidiarrhea
- J1.3.24 Laxatives
- J1.3.25 Anti-emetics
- J1.3.26 Anti-Ulcers
- J1.3.27 Anti-Neoplastic (Anti Cancer) Agents
- J1.3.28 Alkylating
- J1.3.29 Antimetabolites
- J1.3.30 Anti-neoplastic
- J1.3.31 Immunosuppressants
- J1.3.32 Taxoids
- J1.3.33 Respiratory Agents
- J1.3.34 Bronchodilators
- J1.3.35 Antihistamines
- J1.3.36 Antitussives
- J1.3.37 Anti-Rheumatism and Pain Agents
- J1.3.38 Anti-inflammatory
- J1.3.39 Anti-rheumatism
- J1.3.40 Analgesics
- J1.3.41 Anesthetics
- J1.3.42 Agents Against Metabolic Disorders
- J1.3.43 Antidiabetic
- J1.3.44 Antiosteoporotic
- J1.3.45 Thyroid Hormone
- J1.3.46 Steroids
- J1.3.47 Diagnostic Agents

■ J1.4 CHAPTER QUIZZES (Available only in Teaching Package)



○ J2. DRUG DISCOVERY

- J2.1 Introduction
 - J2.1.1 Drug Discovery
 - J2.1.2 Target Identification
 - J2.1.3 Lead Discovery
 - J2.1.4 Lead Optimization
 - J2.1.5 Disciplines Involved in Drug Discovery
- J2.2 Discovery Methods
 - J2.2.1 How Are Leads Discovered?
- J2.3 Serendipity
 - J2.3.1 The Serendipitous Pathway
 - J2.3.2 Penicillin
 - J2.3.3 Aspirin
 - J2.3.4 Glafenine
 - J2.3.5 Furosemide
 - J2.3.6 Chlorpromazine
 - J2.3.7 Cyclosporin A
 - J2.3.8 Viagra
- J2.4 Screening
 - J2.4.1 The Screening Pathway
 - J2.4.2 Example of Molecules Discovered by Screening
- J2.5 Chemical Modification
 - J2.5.1 The Chemical Modification Pathway
 - J2.5.2 Tagamet
 - J2.5.3 Beta-Blockers
 - J2.5.4 Limitation of the Chemical Modification Approach
- J2.6 Rational Drug Design
 - J2.6.1 The Rational Pathway
 - J2.6.2 Captopril Story
 - J2.6.3 Cimetidine Story
 - J2.6.4 The Histamine Action
 - J2.6.5 Screening Molecules Related to Histamine
 - J2.6.6 The Guanidine Analog
 - J2.6.7 The Burimamide Lead
 - J2.6.8 The Metiamide Molecule
 - J2.6.9 The Cimetidine Drug
 - J2.6.10 The Ranitidine Drug
 - J2.6.11 Advantages of Rational Drug Design
- J2.7 Chemistry in Drug Discovery
 - J2.7.1 Chemistry in Drug Discovery
 - J2.7.2 Synthesis of Complicated Molecules
 - J2.7.3 Penicillin
 - J2.7.4 Taxol
 - J2.7.5 Steroid
 - J2.7.6 Three Methods in Synthetic Chemistry
 - J2.7.7 Classical
 - J2.7.8 Parallel
 - J2.7.9 Combinatorial
 - J2.7.10 Chemistry in Lead Discovery
 - J2.7.11 Protein Kinase Example
 - J2.7.12 Chemistry in Lead Optimization
 - J2.7.13 Optimization of the Gleevec Series
 - J2.7.14 CCK-A Receptor Antagonist Example
 - J2.7.15 Chemistry in Drug Development
- J2.8 Patents

- J2.8.1 Intellectual Property and Patents
 - J2.8.2 What Can be Patented?
 - J2.8.3 Requirements for Patentability
 - J2.8.4 Lifetime of a Patent
 - J2.8.5 Effective Patent Lifetime
 - J2.8.6 Patent Protection
- J2.9 CHAPTER QUIZZES (Available only in Teaching Package)
- 

○ J3. DRUG DEVELOPMENT

- J3.1 Introduction
 - J3.1.1 Drug Development
 - J3.1.2 Pipe-Line of Development
 - J3.1.3 Pre-Clinical Development
 - J3.1.4 Clinical Development
 - J3.1.5 Post-marketing Surveillance
 - J3.1.6 Disciplines Involved in Drug Development
 - J3.1.7 Effective Teams: Interactivity and Cooperativity
 - J3.2 The Pre-Clinical Studies
 - J3.2.1 Pre-Clinical Studies
 - J3.2.2 Chemical Development
 - J3.2.3 Pharmacological Studies
 - J3.2.4 Drug Metabolism and Pharmacokinetics
 - J3.2.5 Toxicology Studies
 - J3.2.6 Acute Toxicity
 - J3.2.7 Safety Studies
 - J3.2.8 Carcinogenicity
 - J3.2.9 Mutagenicity
 - J3.2.10 Reproduction Studies
 - J3.2.11 Formulation Development
 - J3.2.12 Stability Tests
 - J3.2.13 Disciplines Involved in Pre-Clinical Development
 - J3.3 Clinical Development
 - J3.3.1 Introduction on Clinical Trials
 - J3.3.2 Clinical Trials Phase 1
 - J3.3.3 Clinical Trials Phase 2
 - J3.3.4 Clinical Trials Phase 3
 - J3.3.5 Clinical Trials Phase 4
 - J3.3.6 Disciplines Involved in Drug Development
 - J3.4 Regulatory Affairs
 - J3.4.1 The Role of the Food and Drug Administration (FDA)
 - J3.4.2 The Investigational New Drug Application (IND)
 - J3.4.3 The New Drug Application (NDA)
 - J3.4.4 The Regulatory Approval Process
 - J3.5 CHAPTER QUIZZES (Available only in Teaching Package)
- 